Company intelligence / Profile preview

ME Therapeutics Holdings Inc.

Vancouver, British Columbia, Canadametherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

ME Therapeutics is advancing its lead anti-G-CSF antibody candidate, h1B11-12, toward first-in-human clinical trials. The company has initiated cell line development for GMP production expected to be completed in the second half of 2025. They have been granted a patent in China for their lead antibody candidate and are awaiting patent examination in the US, Europe, and Canada.

Therapeutic areas: Oncology
Modalities: Antibody drugsSmall molecule prodrugsmRNA-based therapeuticsLipid nanoparticles (LNPs)
Industry: Biotech

Drug pipeline

5 assets

h1B11-12

Preclinical

4 more assets in the full pipeline.

Beyond the preview

Go deeper on ME Therapeutics Holdings Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME Therapeutics Holdings Inc..